EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Efficacy and safety of epcoritamab in relapsed or refractory large B-cell lymphoma: 3-year update from the EPCORE NHL-1 trial

Yasmin H Karimi, Chan Y Cheah, Michael Roost Clausen, David Cunningham, Umar Farooq, Tatyana Feldman, Herve Ghesquieres, Wojciech Jurczak, Kim M Linton, Tycel Phillips, Julie M Vose, Won Seog Kim und 8 weitere

Annals of Hematology · 04.02.2026 · 105 (3)

DOI: 10.1007/s00277-026-06798-4 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Annals of Hematology, online erschienen am 04.02.2026. Verfasst von Yasmin H Karimi und 19 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology/Oncology, University of Michigan, Ann Arbor, MI, USA. karimiy@med.umich.edu. Hauptthemen laut MEDLINE: Antibodies, Bispecific, Lymphoma, Large B-Cell, Diffuse. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Genmab A/S and AbbVie..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Epcoritamab, a CD3xCD20 bispecific antibody, resulted in deep, durable responses with a manageable safety profile in patients with relapsed/refractory large B-cell lymphoma (LBCL) in EPCORE® NHL-1 (NCT03625037). We report results from a 3-year follow-up. Adults with relapsed/refractory LBCL received epcoritamab until progressive disease or unacceptable toxicity. The primary endpoint was overall response rate (ORR). Median age was 64.0 years, 39% of patients received prior CAR T-cell treatment, and 75% were refractory to ≥ 2 consecutive lines of treatment. As of May 3, 2024 (median follow-up 37.1 months [range, 0.3–45.5]), ORR was 59% and complete response (CR) rate 41% by investigator assessment. Median duration of response was 20.8 months (95% confidence interval [CI], 13.0–32.0). Median duration of CR was 36.1 months (20.2–not reached [NR]); the longest ongoing CR was > 43 months. Median progression-free survival was 4.2 months (95% CI, 2.8–5.5) in all patients and 37.3 months (26.0–NR) in patients with CR. Median overall survival was 18.5 months (95% CI, 11.7–27.7) in all patients and NR in patients with CR. Of 119 patients evaluable for minimal residual disease (MRD) assessments, 54 (45%) were MRD-negative at any time during the study. Most common adverse events were cytokine release syndrome (51%), fatigue (25%), and pyrexia (25%), with no new safety signals. Grade 1, 2, and 3 infections occurred in 23%, 34%, and 24% of patients, respectively. The durability of responses and prolonged survival in complete responders suggest long-term disease-free survival with epcoritamab in these patients with relapsed/refractory LBCL.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, BispecificLymphoma, Large B-Cell, DiffuseHumansMiddle AgedFemaleAgedMaleFollow-Up StudiesNeoplasm Recurrence, LocalAged, 80 and overAdultRecurrenceTreatment Outcome

Stichwörter der Autor:innen

3-year follow-upBispecific antibodyEpcoritamabNon-Hodgkin lymphoma

Substanzen

Antibodies, Bispecific

Autor:innen und Institutionen

  • Division of Hematology/Oncology, University of Michigan, Ann Arbor, MI, USA. karimiy@med.umich.edu.
  • Sir Charles Gairdner Hospital, University of Western Australia, Nedlands, WA, Australia.
  • Vejle Hospital, Vejle, Denmark.
  • The Royal Marsden NHS Foundation Trust, Sutton, UK.
  • University of Iowa, Iowa City, IA, USA.
  • John Theurer Cancer Center, Hackensack Meridian Health, Hackensack Meridian Health School of Medicine, Hackensack, NJ, USA.

Förderung

  • Genmab A/S and AbbVie.

Zitieren

APA

Karimi, Y. H., Cheah, C. Y., Clausen, M. R., Cunningham, D., Farooq, U., Feldman, T., Ghesquieres, H., Jurczak, W., Linton, K. M., Phillips, T., Vose, J. M., Kim, W. S., Jafarinasabian, P., D'Angelo Månsson, B., Soong, D., Steele, A. J., Li, Z., Eskelund, C. W., Hutchings, M., & Thieblemont, C. (2026). Efficacy and safety of epcoritamab in relapsed or refractory large B-cell lymphoma: 3-year update from the EPCORE NHL-1 trial. Annals of Hematology, 105(3). https://doi.org/10.1007/s00277-026-06798-4

Vancouver

Karimi YH, Cheah CY, Clausen MR, Cunningham D, Farooq U, Feldman T, et al. Efficacy and safety of epcoritamab in relapsed or refractory large B-cell lymphoma: 3-year update from the EPCORE NHL-1 trial. Annals of Hematology. 2026;105(3). doi:10.1007/s00277-026-06798-4

BibTeX
@article{Karimi2026,
  author = {Karimi, Yasmin H and Cheah, Chan Y and Clausen, Michael Roost and Cunningham, David and Farooq, Umar and Feldman, Tatyana and Ghesquieres, Herve and Jurczak, Wojciech and Linton, Kim M and Phillips, Tycel and Vose, Julie M and Kim, Won Seog and Jafarinasabian, Pegah and D'Angelo Månsson, Barbara and Soong, David and Steele, Andrew J and Li, Zhu and Eskelund, Christian W and Hutchings, Martin and Thieblemont, Catherine},
  title = {Efficacy and safety of epcoritamab in relapsed or refractory large B-cell lymphoma: 3-year update from the EPCORE NHL-1 trial},
  journal = {Annals of Hematology},
  year = {2026},
  volume = {105},
  number = {3},
  doi = {10.1007/s00277-026-06798-4}
}
Kostenlos starten →